Navignostics AG’s Post

It is time to address the elephant in the room! And to conduct a few more well-designed cost-effectiveness studies from a societal perspective. https://lnkd.in/d4n3PxGP

As spring blooms, we welcome April with our co.value® market access quiz! This month's spotlight shines on oncology, exploring the dynamic world of cancer treatment. 💡 Understanding oncology's evolving terrain is vital as we tackle one of healthcare's most critical areas. We invite you to challenge your knowledge and join the dialogue on the latest advancements in cancer care. 👉 Begin April's journey with our quiz: https://lnkd.in/eC74ktAf Dive in and share your insights and scores with us here on LinkedIn. #Oncology #CancerCare #MarketAccess

Our draft guideline is now available for open comment - American Society of Clinical Oncology (ASCO) #ASCO #Cancer #OncoDaily #Oncology #OropharyngealSquamousCellCancer

SIOP Asia 2024 Abstract submission is now open - SIOP Asia 2023 #AbstractSubmission #Cancer #Japan #OncoDaily #Oncology #SIOPAsia #SiopAsia2024

Check our recent publication. #USMIRC

Join us for our Great Debates and Updates meeting series covering both solid and liquid tumor topics throughout the year! Engage in thoughtful discussions with your peers to improve patient care and outcomes. Our meetings are a great opportunity to connect, learn and grow! Check out the dates for our meetings for the remainder of the year: - Great Debates & Updates Hematological Malignancies: April 5-6- NYC - Great Debates & Updates in Lung Cancer : April 27-28- NYC - Great Debates & Updates in Women's Oncology: May 3-4, NYC - Great Debates & Updates Hem/Myeloma Day: May 11 - Dallas - Great Debates & Updates in GI Malignancies: May 17-18 - NYC - Great Debates & Updates Hematological Malignancies: July 27 -28 - Los Angeles - Great Debates & Updates in Lung Cancer : October 5-6 - Dallas - Great Debates & Updates in GI Malignancies: October 19-20 - Dallas - Great Debates & Updates in Women's Oncology: November 1-2 - Nashville If you're interested in attending any of these meetings or need additional information regarding commercial sponsorships, let me know! #oncology #patientcare #healthcare #medicalconference #greatdebates&updates #GDU Great Debates & Updates

Cancer is hitting more young people in the U.S. and around the globe, baffling doctors. Diagnosis rates in the U.S. rose in 2019 to 107.8 cases per 100,000 people under 50, up 12.8% from 95.6 in 2000, federal data show. A study in BMJ Oncology last year reported a sharp global rise in cancers in people under 50, with the highest rates in North America, Australia and Western Europe. https://lnkd.in/gGg4t9uJ

Paper from our lab discussing how MGA delegation drives Richter’s transformation. Very interesting and informative. https://lnkd.in/g9EFpVKE

PATENTS AND INNOVATION AGAINST CANCER Foreword Medical advances are helping many of us to live longer. This means that we are more likely to encounter cancer in our own lives or in those of our closest family and friends. In the European Union, no fewer than 311% of men and 25% of women expected to be diagnosed with cancer before reaching the age of 75 Innovation can give us hope for the future: Over 5 million lives have already been saved in the Ell alone thanks to inventions in oncology The fight against cancer is also increasingly at the forefront of research and innovation, spurred by recent technological breakthroughs and greater commitment from both the private and public sectors. Drawing on the EPO's expertly curated patent data, this study highlights a significant surge in innovation aimed at combatting cancer in recent years with patenting rising by over 70%, or almost 10% annually between 2015 and 2021.. This report offers policymakers and investors bey insights into the drivers behind this trend and their impact on the overall approach to innovation in related industries. The surge in cancer innovation is mainly driven by new technologies-from immunotherapy and gene therapy to digital technologies such as Al-that are opening up promising new avenues for diagnosis and treatment. It also largely sterns from fundamental research, with universities and public research org organisations alone accounting for almost a third of patenting activities. So intellectual property rights (IPRs) play a more important role than ever in supporting the commercialisation of next generation technologies against cancer. Indeed, IPRs not only protect inventions and attract investors, they also support collaboration and technology transfer between research institutions and industry. According to our results, the US enjoys a clear lead in the field of cancer research, accounting for nearly 50% of all IPFs (International Patent Families) from 2002 to 2021, a position boosted in recent years by strong innovation ecosystems and massive public funding. While Europe is in second position, the gap to the LIS is widening and China is catching up at an. impressive pace. The challenge now facing Europe and its policymakers is to increase investment, better exploit its research potential, and to grow its vibrant pool of startups. The newly established Unitary Patent will be instrumental in this endeavour epo.org | 02